VivoSeq
Musculoskeletal

Polyarticular Juvenile Idiopathic Arthritis

7

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Polyarticular Juvenile Idiopathic Arthritis is an early-stage landscape with 7 programs across 2 companies. The most active players are Roche, Bristol-Myers Squibb. 1 therapy is approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

31/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

2 programs

Phase 3Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

9programs
Small molecule444%
Monoclonal antibody444%
Protein / enzyme111%

Modality classified for 100% of 9 pipeline programs.

Analysis

Trial Status

8

clinical trials

Completed8 · 100%

Clinical Trials

Trial Activity

8 trials

Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)
Completed·AAbbott·Phase 3·NCT00048542·171 enrolled
Comparative Study of Leflunomide Plus Methotrexate Versus Methotrexate Monotherapy in Refractory Polyarticular Juvenile Idiopathic Arthritis Patients
Completed·—·Phase 4·NCT07428551·50 enrolled
Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Completed·Roche logoRoche·Phase 3·NCT00144664·19 enrolled
Aggressive Combination Drug Therapy in Very Early Polyarticular Juvenile Idiopathic Arthritis
Completed·HHelsinki University Central Hospital·Phase 3·NCT01015547·60 enrolled
A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis
Completed·Roche logoRoche·Phase 3·NCT00988221·188 enrolled
An Extension Long-Term Study of RoActemra/Actemra (Tocilizumab) in Patients With Polyarticular Juvenile Idiopathic Arthritis Who Completed The WA19977 Study
Completed·Roche logoRoche·Phase 3·NCT01727986·11 enrolled
Pharmacokinetics, Efficacy and Safety of Abatacept Administered Subcutaneously (SC) in Children and Adolescents With Active Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Inadequate Response (IR) to Biologic or Non Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs)
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 3·NCT01844518·219 enrolled
Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Completed·Roche logoRoche·Phase 3·NCT00144625·19 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)